CA2042093C - Cell line carrying an excess of mammalian centromeres - Google Patents

Cell line carrying an excess of mammalian centromeres Download PDF

Info

Publication number
CA2042093C
CA2042093C CA002042093A CA2042093A CA2042093C CA 2042093 C CA2042093 C CA 2042093C CA 002042093 A CA002042093 A CA 002042093A CA 2042093 A CA2042093 A CA 2042093A CA 2042093 C CA2042093 C CA 2042093C
Authority
CA
Canada
Prior art keywords
cells
dna
selectable marker
fragment
dominant selectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002042093A
Other languages
French (fr)
Other versions
CA2042093A1 (en
Inventor
Gyula Hadlaczky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOLOGICAL RESEARCH CENTER OF HUNGARIAN ACADAMY OF SCIENCES (THE
Original Assignee
Gyula Hadlaczky
Biological Research Center Of The Hungarian Acadamy Of Sciences (The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gyula Hadlaczky, Biological Research Center Of The Hungarian Acadamy Of Sciences (The filed Critical Gyula Hadlaczky
Publication of CA2042093A1 publication Critical patent/CA2042093A1/en
Application granted granted Critical
Publication of CA2042093C publication Critical patent/CA2042093C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers

Abstract

DNA fragments and methods for obtaining them are disclosed which when put into mammalian cells together with a dominant marker gene are able to form functional centromeres. The sequences can be used to generate probes for these centromeres. Cell lines containing the functional centromeres are also provided. Methods are taught for isolating mammalian centromeric DNA as well as for producing cell lines car-rying an excess of mammalian centromeres linked to a dominant selectable marker gene.

Description

CELL LINE CARRYING AN EXCESS
OF MAMMALIAN CENTROMERES
BACKGROUND OF THE INVENTION
The centromere is a specialized region of the eukaryotic chro-mosome. It is the site of kinetochore formation, a structure which allows the precise segregation of chromosomes during cell division.
In addition to this, a possible structural role in the higher-order orga-nization of eukaryotic chromosomes has also been suggested (Hadlaczky (1985), Internatl. Rev., 94:57-76).
The isolation and cloning of centromeres is crucial, not only to ts~xstarx3 their molecular structure and functiari, kilt also for the construction of stable artificial chromosomes. Taking advantage of the existence of centromere-linked genes, functional centromeres of lower eukaryotes (yeast) have been successfully isolated (Blackburn, et al. (1984) Ann. Rev. Biochem., 53:163-194; Clarke, et al. (1985), Ann. Rev. Genet., 19:29-56). The combination of a functional centromere with telomeres, which stabilize the chromosome ends, permitted the construction of yeast artificial chmmosomes (Murray, et al. (1983) Nature, 305:189-193; Burke, et al. (1987), Science, 236:806-812). This initiated a new era in the study of chromosome function and in genetic manipulation.
Higher eukaryotes (e.g., mammals), in contrast to yeast, con-tain repetitive DNA sequences which form a boundary at both sides of the centromere. This highly repetitive DNA interacting with cer-tain proteins, especially in animal chromosomes, creates a geneti-cally inactive zone (heterochromatin) around the centromere. This pericentric heterochromatin keeps any selectable marker gene at a considerable distance, and thus repetitive DNA prevents the isolation of centromeric sequences by chromosome "walking.~~
Thus there is a need in the art for methods of isolating higher eukaryotic centromeric DNA. Isolation of such DNA is necessary for construction of artificial mammalian chromosomes; Use of such chromosomes could overcome problems inherent in present tech-niques for introduction of genes to mammalian cells, including the concomitant creation of insertional mutations, size limitations on introduced DNA, and imperfect segregation of plasmid vectors.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a method for isolating centromeric DNA from a mammal.
It is another object of the invention to provide a DNA element which will insure faithful segregation of inserted DNA in meiosis and mitosis.
It is yet another object of the invention to provide a DNA ele-ment for formation of vectors to insert large amounts of DNA into mammalian cells.
It is still another object of the invention to provide a DNA
element which binds mammalian centromere proteins.
These and other objects are provided by one or more of the embodiments described below.
In one embodiment a non-human cell line is provided that contains an excess of centromeres.
In another embodiment a nucleic acid probe is p~d~ which hybridizes to a DNA molecule having the sequence shown in Figure 1.
In yet another embodiment a method of isolating centromeric DNA from a mammal is provided comprising:
isolating metaphase chromosomes of a mammalian cell line;
fragmenting the chromosomes to form a suspension containing chromosome fragments;
incubating the suspension with human serum containing anti-centromere antibodies to bind chromosome fragments to the antibodies;
separating antibody-bound chromosome fragments from the suspension; and deproteinizing said bound fragments to provide a preparation of centromeric DNA.
In still another embodiment a method is provided of producing a cell carrying an excess of mammalian centromeres, comprising:
cotransfecting cells with: (1) DNA carrying mammalian centromeric DNA; and (2) DNA carrying a dominant selectable marker;
selecting cells which express the dominant selectable marker;
detecting cells which carry an excess of mammalian centromeres.
These and other embodiments will be described in more detail below. The present invention thus provides the art with methods to access and isolate the important centromeric DNA of mammalian cells. In particular, a human DNA fragment CM8 is provided which can be used to create artificial chromosomes for gene therapy.
BRIEF DESCRIPTION OF THE DRAWINGS ' Figure 1 provides the sequence of a 13,863 by fragment of DNA identified in a a Charon 4A human genomic library.
Figure 2 shows the results of agarose gel electrophoresis of DNA fragments obtained by immunoprecipitation.
Lanes A and B: DNA isolated from chromosome fragments remaining unbound to anti-centromere Sepharose*
Lanes ~ and D: DNA isolated from chromosome fragments bound to anti-centromere Sepharose. Note the presence of a popula-tion of high molecular weight DNA fragments. Samples of lanes B
and D were treated with 100 ug/ml RNase-A prior to electrophoresis.
Lane M: a FiindIII marker.
Figure 3 shows a restriction map of the human genomic DNA
insert of CM8 a Charon 4A clone. The arrow shows the position of a 300 by Alu repeat deficient in the flanking direct repeat sequences.
Figure 4 shows the results of in situ hybridization with 3H-thymidine labelled CM8 DNA to human metaphase chromosomes.
Panel A: Preferential localization of silver grains at the centromeres of human chromosomes (arrowheads).
* TYademarlc Panel B: Diagram showing the distribution of silver grair~ (') on 131 metacentric chromosomes. Numbers indicate the frequency of silver grain localization to certain regions of the chromosomes.
Figure 5 shows the detection of dicentric and minichromosome of the EC3/7 cells by indirect immunofluorescence (panels A and B) with anti-centromere antibodies, and by in situ hybridization with biotin labelled CM8 probes (panel C) and with a 1 kb SmaL/BgIII frag-ment of APH-II gene (panel D).
Panels E and F: DNA staining with Hoechst 33258;
Panels G and H: DNA staining with propidium iodide. Panels E-H correspond to A-D, respectively. Arrowheads point to dicentric and minichromosomes.
Figure 6 shows the duplication of the extra centromere in the EC3/7 cell Line.
Panels A-C: In situ hybridization with biotin labelled CM8 probe.
Panels D-F: Corresponding DNA staining of A-C, respectively.
Figure 7 demonstrates the colocalization of the integrated DNA sequences with the centromere region detected by immunostaining with anti-centromere serum (Panels A and D) and subsequent in situ hybridization with 'biotin labelled CM$ (panel B) and APH-II probe (panel E) on the same metaphases of the EC3/7 cells.
Panels C and F: DNA staining.
DETAILED DESCRIPTION
It is the discovery of the present invention that a segment of human DNA can be isolated and introduced into mouse cells and result in a a functional centromere. The functional centromeres containing DNA of the present invention are prelerably linked to a domi-nant selectable marker. This can be a resistance marker, such as the aminoglycoside-3' phosphotransferase-II which provides resistance to 6418 (Sigma). Other such markers known in the art may be used.
The method of isolating centromerie DNA of the present invention can be applied to any higher eukaryote, especially mam-mals. Preferably a human cell line will be employed. Metaphase 204.203 chromosomes are isolated according to techniques known in the art.
The chromosomes are then fragmented. Endonuclease digestion and mechanical shearing can be used to fragment the chromosomes.
Desirably the majority of the fragments will be in the size range of less than 1 um and some chromosomes will remain unbroken. Unbro-ken chromosomes can be readily removed from the preparation by centrifugation at about 1,500 g for about 10 minutes.
A human serum containing anti-centromere autoantibodies can be employed in the method of the invention. This is available from patients with CREST syndrome. Alternative sources of antibody may be used, such as monoclonal or animal derived polyclonal sera con-taining anti-eentromere antibodies. The antibodies are incubated with the preparation of chromosome fragments under condition where antibody-antigen complexes form and are stable. It is conve-nient it the antibodies are hound to a solid support. Preferably a sup-port such as Protein-A Sepharose CL4B (Fharmacia) is used to facili-tate separation of bound flrom unbound chromosomal fragments.
However other methods to accomplish this goal can be used, as are known in the art, without employing an antibody bound to a solid support.
The DNA fragments comprising centromere DNA are liberated from the antibodies and centromeric proteins by a deproteinization treatment. Ultimately the DNA is purified from all proteins, try degrading the proteins and extracting them from the chromosome fragment preparation. Any such treatment known in the art may be used including but not limited to proteases and organic solvents such as proteinase K and phenol.
The centromeric DNA fragments can be used for any purpose or application known in the art. For example, they can be labelled and used as probes; they can be ligated to vectors to clone or all part of the sequences; and they can be used to purify centromeric proteins by attachment to a solid support.
In one particular embodiment of the invention the centmmeric DNA fragments are used to probe a library of genomic DNA from humans or other mammals for clones which hybridize. Hybridizing * 'I~-ac~nar)c C

~4~~~~3 -s-clones can be analyzed for their ability to perform functions which centromerie DNA possesses. One such function is to bind to centromeric proteins. Another such function is to form a structure in cells which can be cytologically detected using appropriate immunostaining with -anti-centromere ~ antibodies which particularly stain centromeres.
According to another method of the present invention a cell carrying an excess of mammalian centromeres is formed. The cell may be human or other mammalian. The centromere may comprise DNA isolated from the same or a different mammalian species as the cell. The method involves cotransfection of a cell with two DNA
moleeule~: one is a DNA carrying centromeric DNA; the other is a DNA carrying a dominant selectable marker. Preferably these two DNA molecules contain sequences which allow concatamer forma-tion, for example phage DNAs such as a phage. The first DNA mole-cule may be isolated from a library of genomic DNA using, for exam-ple, as a probe the centromeric fragments taught above. Alterna-tively the first DNA molecule may result from cloning the centromeric fragments taught above into a phage, for example a, after manipulations to create fragments of the appropriate sizes and termini. The second DNA molecule is readily within the reach of those of skill in the art, for example a a phage carrying a drug resis-tance marker.
It is believed to be desirable to employ ~ phage DNA because ft concatemerizes, however the absolute necessity of this has not been determined. Further, even if this property is necessary, other viral DNAs or DNA constructs maybe able to supply this function. Such other means of achieving concatemerization are also contemplated within this method.
After cotransfeetion, cells are selected which express the dominant selectable marker, for example by growth in amounts of 6418 which are cytotoxic for the cells without the marker. This selected population of cells is further screened to detect cells with an excess of mammalian centromeres. This screening can be done by standard cytogenetie techniques, as well as by immunostafning with anti-centromere antibodies. Desirably the lambda, marker, and centromeric DNA (from the ~ clone) will all be localized at the site of the extra centromere. This can be determined by in situ hybridization studies, which are well known in the art.
One cell line made by t:he methods described above is EC3/7 which has been deposited at the European Collection of Animal Cell Cultures, Porton Down, U.K. under accession no. 90051001 (deposit date October 5, 1990) under the conditions of the Budapest Treat y.
The sequence of the DNA insert in the lambda phage which was used to make the EC3/7 cell line, {referred to as CM8) was determined by standard techniques and is shown in Figure 1. The sequence does not correspond to any in DNA
sequence banks.
The present invention also contemplates nucleic acid probes, preferably of at least 10 nucleotides, which hybridize to a DNA molecule having the sequence shown in Figure 1. One such molecule is CM8, the lambda phage clone from which the sequence was derived. Probes can be radiolabeled, biotin labeled or even unlabeled, for example, depending on the use for which they are desired.
The following examples do not limit the invention - 7a -to the particular embodiments described, but are presented to particularly describe certain ways in which the invention may be practiced.
Pxample 1 This example demonstrates the isolation of human DNA from centromeres.
Human colon carcinoma cell line (Colo 320) was grown as a suspension in RPMI medium supplemented with 10~
foetal calf serum (FGS). Metaphase chromosomes of Colo 320 cells were isolated by our standard method (Hadlaczky, et al.
(1982), Chromosames, 86:643-659). Isolated metaphase chromosomes were resuspended in 1 ml of buffer (105 mM NaCl, 50 mM Tris-HC1 pH 7.5, 10 mM MgCl2, 5 mM

20~.249~

2-mercaptoethanol) at a concentration of 1 mg/ml DNA and digested with 500 a EcoRI restriction endonuclease for 1 h. The suspension was dilated with 4 ml of IPP buffer (500 mM NaCI, 10 mM Tris-HCI, 0.596 NP-40; pH 8.0) and sonicated for 5x50 s with an MSE 5-70 sonicator. This treatment resulted in a suspension containing chro-mosome fragments and a few (< 196) unbroken small chrnmosomes.
The suspension was centrifuged at 1500 g for 10 min to remove unbro-ken chromosome fragments. The supernatant contained only small (<_ 1 um) chromosome fragments as judged by light microscopy.
Two hundred fifty mg of Protein-A Sepharese~ CL4B
(Pharmacia) was swollen in IPP buffer and incubated with 500 u1 human anti-centromere serum LU851 (Hadlaczky, et al. (1989), Chromosoma, 97:282-288) diluted 20-fold with IPP buffer. Suspension -of sonicated chromosome fragments (5 ml) was mixed with anti-centromere S~pharo~e (1 ml) and incubated at room temperature for 2 h with gentle rolling. After 3 subsequent washes with 25 ml IPP
buffer the Sepharose was centrifuged at 2008 for 10 min.
Isolation of DNA from the immunoprecipitate was carried out by Proteinase-K treatment (Merck, I00 ug/ml) in 10 mM Tris-HCI, 2.5 mM EDTA f pH 8.0 containing 196 SDS, at 50 ° C overnight, followed by repeated phenol extraetions and precipitation with isopropanol. ~4ll general DNA manipulations were done according to (Maniatis, et al.
(1982) Molecular Cloning-A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
Results of electrophoresis of immunoprecipitated and superna-tant DNA are shown in Figure 2. The bulk of DNA from chromosome fragments which did not bind to the anti-centromere Sepha~se*
(supernatant) ranged from several hundred base pairs to 5 kb (Fig. 2, lanes A and B), while DNA from chromosome fragments which bound to the anti-centromere Sepharose contained an additional population of high molecular weight (9-20 kb) fragments (Fig. 2, lanes C and D).
This distribution of fragments sizes is consistent with the notion that the centromeric DNA is in the sfructurally most stable region of mammalian chromosomes (Hadlaezky, et al. (1981), Chromovsoma, * Trademark C
4~4~~

81:55?-56?), thus rendering this DNA relatively resistant to enzy-matic digestion and mechanical shearing.
Example 2 This example demonstrates the use of the high molecular weight immunoprecipitated DNA as a hybridization probe to screen a genomic DNA library.
The high molecular weight DNA was isolated from the agarose gel described in Example l, by electroelution, labelled with 32P-dATP
by random oligonucleotide priming (Feinberg, et al. (1983), Anal.
Biochem., 132:6-13) end used as a probe for screening a a Charon 4A
human genomie library (Maniatis, et al. (19?8), Cell, 15: 68?-?01). A
hybridizing clone (CM8) was obtained which contains a 14 kb human DNA insert. The restriction map of this insert for some restriction endonucleases is shown in Figure 3. Southern hybridization of parts of the 14 kb insert to human Iymphoeytic genomic DNA indicates that the 14 kb insert represents a continuous piece of DNA in the genome and is not the ligation product of a number of fragments.
Example 3 This example demonstrates that the copy number of the i4 kb insert of clone ~CM~is consistent with it being present on each chro-mosome in the human genome.
Southern blotting experiments were performed in which a sin-gle copy DNA probe (XV2C) (Estivill, et al. (198?), Nature, 326:840-845) and the central XhoI-EcoRI fragment of the CMS insert (Fig. 2) simultaneously hybridized with serial dilutions of human peripheral lymphocyte DNA. The probes were labelled by random oligonucleotide priming (Feinberg, et al. (1983), Anal. Biochem., 132:6-13). By comparing the signal of the CM8 probe to the lyown single copy probe, the copy number of CM8 was estimated to be 16-32 per haploid genome.
Example 4 This example shows the use of the CM8 DNA as a probe to human metaphase chromosomes.
Radioactive in situ hybridization with 3H-thymidine labelled CM8 DNA to human (Colo 320) metaphase chromosomes was -lo- 2042093 performed according to the method of Pinkel, et al. (1986), Proc.
Natl. Acad. SeL USA, 83:2934-2938. A preferential centromeric localization of silver grains was observed (Fig. 4).
In non-radioactive in situ hybridization according to the method of (Graham, et al. (1973), Virology, 52:456-467), using biotin-labelled subfragments or the whole CM8 insert it was not possible to detect a positive hybridization signal by our standard method. Fur thermore, using a hybridization method which is suitable for single copy gene detection with a biotin-labelled probe (Lawrence, et al.
(1988), Cell, 52:51-61), apart from the typical R-band like Alu hybrid-ization pattern (Korenberg, et al. (1988), Cell, 53:391-400), no spe-cific hybridization signal was detected on any of the chromosomes with the whole 14 kb CM8 insert. Possible explanatiorLS for this nega-tive result are that these sequences are virtually inaccessible to the hybridization probe, due to their compact packing in the midst of the centromere structure, and that the biotin system is less sensitive than the radioactive one.
Example 5 This example discloses the sequence of the human CM8 clone.
The sequence of the human genomic insert of a CM8 was determined using the dideoxy method (Sanger, et al. 91980), J. Mol.
Biol., 143:161-178; Biggin, et al. (1983), Proc. Natl. Acad. Sci. USA, 80:3963-3965). See Figure 1.
The sequence of the 13,863 by human CM8 clone was com-pared with a complete nucleic acid data bank (MicroGenie, Beckman) and showed no homology to any known sequence. However, a 300 by Alu repeat deficient in the flanking direct repeat sequences was found in the 2.5 kb EcoRI-Xhol fragment (Fig. 3), which explains the Alu type in situ hybridization pattern.
Example 6 This ~example demonstrates the use of the~CMB DNA to form centromeres in mammalian cells.
In order to detect any in vivo centromere function of the CM8 DNA, it was introduced with the selectable APH-II gene into mouse * ~c 20~-~~9~

LMTK fibroblast cells. The mouse fibroblast cells were maintained as a monolayer in F 12 medium supplemented with 1096 FCS. The calcium phosphate method (Harger, et al. (1981), Chromosama, 83:431-439) was used to transfect the cells with 20 ug a CM8 and 20 ug a gtWESneo DNA per Petri dish (80 mm). A 2 minute glycerol shock was used. The agt WESneo was made by cloning the pAG60 plasmid (Colbere-Garapin, et al. (1981), J. Mol. Biol., l5tTa-14) into a a gtWES (Leder, et al. (1977), Science, 196:1?5-177) bacteriophage vector:
The whole a CM8 and a gt WESneo constructions were used for transfeetions for two reasons. First, to separate the marker gene from the CM8 sequences, in order to avoid inactivating the APH-II
gene, a process which may occur during centromere formation. Sec-ond, a DNA is capable of forming long tandem arrays of DNA mole-cules by eoncatamerization. Coneatamerization was postulated as ~being necessary to form centromeres since, in S. pombe 4 to 15 copies of conserved sequence motifs form centromeres (Chikashige, et al.
(1989), Cell, 57:739-751). Considering these two facts,a multiplica-tion of the putative centromeric DNA by concatamerization might increase the chance of centromere formation.
Transformed cells were selected on growth medium containing 400 ug/ml 6418 (Genticin, Sigma). ~ Individual 6418. resistant clones were analyzed. The presence of human sequences in the transformed clones was monitored using Southern blots probed with subfragments of the CM8 insert. Screening for excess centromeres was achieved by indirect immunofluorescence using human anti-centromere serum LU851 (Hadlaczky; et al. (1989), Chromosoma, 97:282-288). The chro-mosomal localization of t°foreign" DNA sequences was determined by in situ hybridization with biotin labelled probes.
Eight transformed clones have been analyzed. All of the clones contained human DNA sequences integrated into mouse chro-mosomes. However, only two clones (EC5/6 and EC3/7) showed the regular presence of dicentric chromosomes. Individual cells of clone EC5/6 carrying di-, tri-, and multicentromeric chromosomes exhib-ited extreme instability. In more than 6096 of the cells of this cell 204~20~3 line the chromosomal localization of the integrated DNA sequences varied from cell to cell. Due to this instability, clone ECS/6 was deemed to be unsuitable. However, cells of clone EC3/? were stable, carrying either a dicentric (8596) or a minichromosome (1096).
Centromeres of dicentric chromosomes and minichromosomes were indistinguishable from the normal mouse centrnmeres by immunostaining with anti-centromere antibodies (Fig. 5A and B).
Example 7 This example shows that the newly introduced DNA in the EC3/? cell line contributes to centromere formation.
In situ hybridization with biotin labelled CMB, APH-II gene, and a phage DNA were carried out. Chromosomes were counterstained with propidium iodide (Pinkel, et al. (1986), Proe.
Natl. Acad. Sci. USA, 83:2934-2938) for in situ hybridization experi-ments while in indirect immunofluorescence with DNA binding dye, Hoechst 33258 used. All observations and microphotography were made by using an -Qlympus AHBS Vanox microscope. Forte 40~~1Pro-fessional black and white, and Fujicolor 400 Super HG colour film were used for photographs.
Without exception these three probes hybridized onto the same spots: either on the distal centromere of the dicentrie chromosome (Fig. 5C) or on the centromere of the minichmmosome (Fig. 5D). In less than 596 of the EC3/7 cells an alternative localization of the hybridization signal was found. These included cells with more than one integration site, cells without a detectable signal, or cells where the hybridization was found on ehromo~somes other than that identi-fied as the dicentric chromosome, In less than 0.596 of the cells a tandem array of the hybridiza-tion signal was observed on the dicentric chromosomes (Fig. 6A-C), suggesting that the additional centromere was capable of autonomous "duplication." At least some of these duplicated centromeres appeared to be functional. This was indicated by the existence of a minichromosome with double centmmeres. Both centmmeres of this minichromosome showed positive immunostaining with anti-centromere antibodies (Fig. 7A). Minichromosomes carrying * Trademark 2042J~:3 double centromeres might be breakage products of multicentromeric chromosomes.
Indirect immunofluorescence of mouse metaphase cells was performed as described by Hadlaczky, et al. (1989), Chromosome, 97:282-288. When indirect immunofluorescence and in situ hybridiza-tion were performed on the same metaphases, mitotic cells were resuspended in a glycine-hexylene glycol buffer (Hadlaczky, et al.
(1989), Chromosome, 9?:282-288), swollen at 37°C for 10 min fol-lowed by cytocentrifugation and fixation with cold (-20°C) methanol.
After the standard immunostaining (Hadlaczky, et al. (1989), Chromosome, 97:282-288) metaphases were photographed, then coverslips were washed off with phosphate buffered saline and slides were fixed in ice-cold methanol-acetic acid, air-dried and used for in situ hybridization.
To demonstrate the integration of the humanCM8 clone and the APH-II gene in the centromere region, immunostaining of centromeres with anti-centromere antibodies followed by in situ hybridization with CM8 and APH-II probes was carried out on the same metaphase plates of EC3/7 cells. The in situ hybridization sig-nals with both biotin-labelled CM8 and APH-II probes showed a colocalization with the immunostained centromeric region of the chromosomes carrying additional centromeres (Fig. 7).
Example 8 This example describes the stability of the EC3/? cell line.
Forty-six independent subclones derived from a single cell were isolated and analyzed. Each of the subclones carried the dicentric chromosome. The percentage of minichrnmosome-contain-ing cells varied between 296 and 3096 in different subclones. We were unable to isolate a subclone which carried the additional centromere exclusively in a minichromosome. This result suggested that the minichromosomes were unstable and they can be regarded as the products of regular breakages of the dicentric chromosomes.
A preliminary analysis by immunostaining of EC3/7 cells (103 metaphases) cultured for 46 days in non~elective medium showed that 80.696 of the cells contained either a dicentric (60.296) or a ,~~~...

minichromosome -(20.496). Subsequent in situ hybridization with biotfn labelled probes proved the presence of the ~~foreign~~ DNA in the additional centromere. 'these results indicate that no serious loss or inactivation of the additional centromeres had occurred during this period of culture under non-selective conditions.
Example 9 This example shows that the CM8 insert concatamerized to form the functioning centromere of cell line EC3/?.
DNA of the EC3/? cell line and human lymphocyte DNA were digested with restriction endonueleases and probed with subfragments of the CM8 insert in a Southern hybridization experiment. . Compar-ing the intensity of the hybridization signal with EC3/7 DNA to that with the human DNA, the ~ .minimum numlaer of integrated human sequences in the -additional centromere was estimated to be >30. The copy number of CM8 in human lymphocytie DNA was determined as described above in Example 3.

Claims (25)

1. A non-human mammalian cell line, comprising cells that contain an excess of centromeres, wherein said cells comprise human DNA having the restriction fragment map as set forth in Figure 3 or a fragment thereof.
2. A rodent cell line, comprising cells that contain an excess of centromeres, wherein:
a) said cells comprise human DNA having the restriction fragment map as set forth in Figure 3 or a fragment thereof; and b) human autoantibodies isolated from CREST syndrome patients bind to one or more chromosomes in cells in the cell line.
3. A cell that is selected from cells that have all of the identifying characteristics of the cells deposited at the European Collection of Animal Cell Cultures (ECACC) under accession no. 90051001.
4. A cell line having all of the identifying characteristics of the cells deposited at the European Collection of Animal Cell Cultures (ECACC) under accession no. 90051001.
5. A rodent cell line produced by a method comprising the steps of:
a) cotransfecting cells with a DNA fragment comprising human DNA
and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in figure 3 or a fragment thereof;
b) growing the cells and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres.
6. A rodent cell line produced by a method comprising the steps of:

a) cotransfecting cells with a DNA fragment comprising human DNA
and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in figure 3 or a fragment thereof;
b) growing the cells under selective conditions. and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres that include a chromosome with two centromeres.
7. A rodent cell line produced by a method comprising the steps of:
a) cotransfecting cells with a DNA fragment comprising human DNA
and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in figure 3 or a fragment thereof;
b) growing the cells under selective conditions and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres that include a minichromosome, wherein the minichromosome is smallest chromosome in the cell.
8. A cell or cell line according to any one of claims 1 to 7, wherein said human DNA comprises the nucleotide sequence set forth in Figure 1.
9. A cell or cell line according to claim 8, wherein the cells are mouse cells.
10. A method of producing a mammalian cell containing an excess of functional centromeres, comprising:
a) cotransfecting cells with a DNA fragment comprising human DNA
and a DNA fragment encoding a dominant selectable marker, wherein said human DNA comprises CM8;

b) growing the cells and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres.
11. The method of claim 10, wherein said human DNA comprises the nucleotide sequence set forth in Figure 1.
12. The method of claim 11, wherein the cells that express the dominant selectable marker and have an excess of mammalian centromeres are cells that have all of the identifying characteristics of the cells deposited at the European Collection of Animal Cell Cultures (ECACC) under accession no. 90051001.
13. The method of claim 12, wherein the human DNA is contained in the clone A CM8 and the selectable marker is encoded by .lambda. gt WESneo.
14. A method of producing mammalian cells containing a dicentric chromosome, comprising:
a) cotransfecting cells with a DNA fragment comprising human DNA
and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in Figure 3 or a fragment thereof;
b) growing the cells under selective conditions and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres that include a chromosome with two centromeres.
15. A method of producing mammalian cells containing a minichromosome that contains heterologous DNA, comprising:
a) cotransfecting cells with a DNA and a DNA fragment comprising human DNA and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in Figure 3 or a fragment thereof;
b) growing the cells under selective conditions and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres that include a minichromosome, wherein the minichromosome is smallest chromosome in the cell.
16. A method of producing a mammalian cell containing an excess of centromeres, comprising:
a) cotransfecting cells with a DNA and a DNA fragment comprising human DNA and a DNA fragment encoding a dominant selectable marker, wherein said human DNA has the restriction fragment map as set forth in Figure 3 or a fragment thereof;
b) growing the cells and selecting cells that express the dominant selectable marker;
c) detecting among the cells that express the dominant selectable marker those cells with an excess of mammalian centromeres.
17. The method of any of claims 14 to 16, wherein said human DNA
fragment comprises the human DNA in the clone .lambda. CMB.
18. The method of any of claims 14 to 16, wherein said human DNA
comprises the nucleotide sequence set forth in Figure 1.
19. The method of any of claims 11-18, wherein the selectable marker encodes aminoglycoside-3 phosphotransferase-II.
20. A DNA molecule having the restriction map as set forth in Figure 3 or a fragment thereof.
21. A DNA molecule having the nucleotide sequence as set forth in Figure 1 or a fragment thereof.
22. A minichromosome derived from the cell line of claim 4.
23. A minichromosome isolated from the cells produced by the method of claim 15.
24. A dicentric chromosome derived from the cell fine of claim 4.
25. A minichromosome isolated from the cells produced by the method of claim 14.
CA002042093A 1990-05-09 1991-05-08 Cell line carrying an excess of mammalian centromeres Expired - Fee Related CA2042093C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52107390A 1990-05-09 1990-05-09
US521,073 1990-05-09

Publications (2)

Publication Number Publication Date
CA2042093A1 CA2042093A1 (en) 1991-11-10
CA2042093C true CA2042093C (en) 2002-12-24

Family

ID=24075224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002042093A Expired - Fee Related CA2042093C (en) 1990-05-09 1991-05-08 Cell line carrying an excess of mammalian centromeres

Country Status (6)

Country Link
US (2) US5712134A (en)
EP (1) EP0473253B1 (en)
JP (1) JP3382256B2 (en)
AT (1) ATE250134T1 (en)
CA (1) CA2042093C (en)
DE (1) DE69133310T2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US5288625A (en) * 1991-09-13 1994-02-22 Biologic Research Center Of The Hungarian Academy Of Sciences Mammalian artificial chromosomes
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
EP2060633A1 (en) 1996-08-26 2009-05-20 Chromo Research, Inc. Mammalian artificial chromosomes
US6265211B1 (en) 1997-05-13 2001-07-24 Amrad Operations Pty. Ltd. Nucleic acid molecules comprising a neocentromere
US7235716B2 (en) 1997-06-03 2007-06-26 Chromatin, Inc. Plant centromere compositions
US7227057B2 (en) 1997-06-03 2007-06-05 Chromatin, Inc. Plant centromere compositions
CA2292893C (en) * 1997-06-03 2012-01-17 Arch Development Corporation Plant artificial chromosome (plac) compositions and methods
US6972197B1 (en) 1999-03-18 2005-12-06 The University Of Chicago Plant chromosome compositions and methods
US7119250B2 (en) 1997-06-03 2006-10-10 The University Of Chicago Plant centromere compositions
US6900012B1 (en) 1997-06-03 2005-05-31 The University Of Chicago Plant artificial chromosome compositions and methods
US7193128B2 (en) 1997-06-03 2007-03-20 Chromatin, Inc. Methods for generating or increasing revenues from crops
US7989202B1 (en) 1999-03-18 2011-08-02 The University Of Chicago Plant centromere compositions
CA2421267C (en) * 2000-09-28 2009-01-06 Bioriginal Food & Science Corporation Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
US7294511B2 (en) 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US6936469B2 (en) 2001-03-22 2005-08-30 Chromos Molecular Systems Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030186390A1 (en) * 2001-03-22 2003-10-02 De Jong Gary Methods for delivering nucleic acid molecules into cells and assessment thereof
BR0209989A (en) * 2001-05-30 2005-04-12 Chromos Molecular Systems Inc Chromosome-based platforms
EP1401849A4 (en) * 2001-05-30 2005-05-18 Chromos Molecular Systems Inc Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
JP2003135075A (en) * 2001-11-05 2003-05-13 Research Association For Biotechnology NEW FULL-LENGTH cDNA
WO2003093469A2 (en) * 2002-05-01 2003-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US7330851B2 (en) * 2003-08-18 2008-02-12 Eaglehawk, Limited Data security through dissembly of data elements or connections between elements
EP1718754A1 (en) * 2004-02-23 2006-11-08 Chromatin, Inc. Plants modified with mini-chromosomes
WO2007030510A2 (en) 2005-09-08 2007-03-15 Chromatin Inc. Plants modified with mini-chromosomes
US20090165176A1 (en) * 2006-05-17 2009-06-25 Pioneer Hi-Bred International, Inc. Artificial Plant Minichromosomes
EP2308986B1 (en) * 2006-05-17 2014-10-08 Pioneer Hi-Bred International Inc. Artificial plant minichromosomes
US8614089B2 (en) * 2007-03-15 2013-12-24 Chromatin, Inc. Centromere sequences and minichromosomes
WO2011011693A1 (en) 2009-07-23 2011-01-27 Chromatin, Inc. Sorghum centromere sequences and minichromosomes
HU230368B1 (en) 2012-11-16 2016-03-29 Magyar Tudományos Akadémia Szegedi Biológiai Kutatóközpont A novel method to load a mammalian artificial chromosome with multiple genes
WO2017180786A2 (en) 2016-04-12 2017-10-19 Edward Perkins Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NL8200523A (en) * 1982-02-11 1983-09-01 Univ Leiden METHOD FOR TRANSFORMING IN VITRO PLANT PROTOPLASTS WITH PLASMIDE DNA.
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4806476A (en) * 1983-09-08 1989-02-21 Lovelace Medical Foundation Efficient cell fusion process
US4608339A (en) * 1983-10-25 1986-08-26 Yoakum George H Protoplast fusion method for high-frequency DNA transfection in human cells
FR2569723B1 (en) * 1984-08-31 1986-09-19 Centre Nat Rech Scient APPLICATION OF ANTIBIOTICS FROM THE PHLEOMYCIN FAMILY AS A SELECTION AGENT IN THE FIELD OF GENETIC ENGINEERING
US4686186A (en) * 1984-09-26 1987-08-11 Wisconsin Alumni Research Foundation Recombinant vector and eukaryotic host transformed thereby
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4970162A (en) * 1985-11-13 1990-11-13 The United States Of America As Represented By The Department Of Health And Human Services Human-mouse hybrid cell line expressing monocyte-macrophage properties
US4935350A (en) * 1985-11-18 1990-06-19 Amgen Materials and methods for controlling plasmid copy number and stability
FR2593827B1 (en) * 1986-01-31 1989-12-22 Inst Nat Sante Rech Med DNA FRAGMENTS FOR USE IN VECTORS FOR THE HEREDITARY MAINTENANCE OF AUTONOMOUS FOREIGN GENES IN TRANSGENIC ANIMALS, PROCESS FOR THEIR PRODUCTION AND BIOLOGICAL APPLICATIONS
US4784737A (en) * 1986-04-18 1988-11-15 The United States Department Of Energy Electromicroinjection of particles into living cells
US5215914A (en) * 1986-06-18 1993-06-01 American Registry Of Pathology Adherent and invasive mycoplasma
ES2091179T3 (en) * 1986-07-24 1996-11-01 Daiichi Seiyaku Co AUTONOMIC REPLICATION DNA FRAGMENTS, DERIVED FROM MAMMALIAN CELLS AND THAT HAVE AN AFFINITY WITH RESPECT TO THE PROTEINS FIXED IN DNA.
US5364761A (en) * 1986-07-24 1994-11-15 Daiichi Pharmaceutical Co., Ltd. Method for isolating a DNA encoding an autonomously replicating sequence
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
DE68925030T2 (en) * 1988-01-21 1996-07-25 Massachusetts Inst Technology MOLECULE TRANSPORT THROUGH FABRICS WITH THE USE OF ELECTROPORATION.
EP0350052A3 (en) * 1988-07-06 1991-04-03 Daiichi Pharmaceutical Co., Ltd. Transgenic animals transformed with autonomously replicating sequence-containing plasmid
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
GB8823068D0 (en) * 1988-09-30 1988-11-09 Ici Plc Recombinant dna
CA2006011A1 (en) * 1988-12-21 1990-06-21 Cecilia Lo Transgenic organisms and cells and methods of producing transgenic organisms and cells
US5272262A (en) * 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5144019A (en) * 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
DK168302B1 (en) * 1989-06-29 1994-03-07 Danisco Method of introducing molecules, especially genetic material into plant cells
US5501967A (en) * 1989-07-26 1996-03-26 Mogen International, N.V./Rijksuniversiteit Te Leiden Process for the site-directed integration of DNA into the genome of plants
GB8918226D0 (en) * 1989-08-09 1989-09-20 Wellcome Found Dna assays
US5550318A (en) * 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5434086A (en) * 1989-08-22 1995-07-18 The Regents Of The University Of Michigan Method of testing potential cystic fibrosis treating compounds using cells in culture
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5149796A (en) * 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
EP0497922B1 (en) * 1989-10-24 2002-01-30 Chiron Corporation Infective protein delivery system
US5292658A (en) * 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5436392A (en) * 1990-01-12 1995-07-25 Arizona Technology Development Corporation Transgenic plants expressing M. sexta protease inhibitor
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US5269590A (en) * 1990-05-21 1993-12-14 Carilli Brian D Multi-layer high impact seating
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
US5382524A (en) * 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
WO1992007950A1 (en) * 1990-10-25 1992-05-14 Clague Pitman Hodgson Method of gene transfer using retrotransposons
US5461032A (en) * 1991-03-01 1995-10-24 Fmc Corporation Insecticidally effective peptides
DK0576483T3 (en) * 1991-03-11 2001-10-08 Syngenta Ltd Biocidal proteins
US5240840A (en) * 1991-04-05 1993-08-31 Regents Of The University Of Michigan Dna superfragment cloning
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5288625A (en) * 1991-09-13 1994-02-22 Biologic Research Center Of The Hungarian Academy Of Sciences Mammalian artificial chromosomes
JPH06505400A (en) * 1991-10-15 1994-06-23 パウダージェクト ヴァクシンズ, インコーポレイテッド Particle-mediated transformation of mammalian nonadherent cells
US5260191A (en) * 1992-01-30 1993-11-09 Agracetus, Inc. Method for diagnosing tumors
US5266600A (en) * 1992-02-28 1993-11-30 Bristol-Myers Squibb Company BU-4641V, an antibacterial, antiviral and antitumor antibiotic
JP3314241B2 (en) * 1992-04-06 2002-08-12 ヤマハ発動機株式会社 Exhaust gas purification device for motorcycle engine
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
CA2100116C (en) * 1992-07-09 2001-09-18 Joseph M. Jilka Virus resistant plants
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
IL108707A (en) * 1993-02-19 1999-06-20 Weiner David B Pharmaceutical compositions and diagnostic kits comprising hiv protein vpr or proteins that bind to vpr
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
AU7177494A (en) * 1993-06-25 1995-01-17 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
US5468615A (en) * 1993-07-01 1995-11-21 The Upjohn Company Binding assay employing a synthetic gene for D4 dopamine receptors
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
JPH09509046A (en) * 1993-11-29 1997-09-16 ユニヴァーシティ オブ サウス フロリダ Transgenic mouse
JPH09508267A (en) * 1994-01-19 1997-08-26 ザ ウェルカム トラスト リミテッド アズ トラスティー トゥー ザ ウェルカム トラスト Natural resistance binding macrophage protein and use thereof
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
GB9410446D0 (en) * 1994-05-25 1994-07-13 Cancer Res Campaign Tech Novel chromosome fragment

Also Published As

Publication number Publication date
US5891691A (en) 1999-04-06
EP0473253B1 (en) 2003-09-17
JPH06121685A (en) 1994-05-06
EP0473253A1 (en) 1992-03-04
JP3382256B2 (en) 2003-03-04
ATE250134T1 (en) 2003-10-15
DE69133310T2 (en) 2004-07-08
CA2042093A1 (en) 1991-11-10
US5712134A (en) 1998-01-27
DE69133310D1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
CA2042093C (en) Cell line carrying an excess of mammalian centromeres
Sart et al. A functional neo-centromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA
Gyurkovics et al. A new homeotic mutation in the Drosophila bithorax complex removes a boundary separating two domains of regulation.
US20070117202A1 (en) Novel nucleic acid molecule
Hadlaczky et al. Centromere formation in mouse cells cotransformed with human DNA and a dominant marker gene.
Wigler et al. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor
Rio et al. Identification and purification of a Drosophila protein that binds to the terminal 31-base-pair inverted repeats of the P transposable element.
Yang et al. Higher order structure is present in the yeast nucleus: autoantibody probes demonstrate that the nucleolus lies opposite the spindle pole body
JP3298842B2 (en) Transgenic or chimeric animals produced by genomic site-specific insertion of foreign genes
JP4022835B2 (en) Mammalian artificial chromosome
Matzke et al. A 41–42 bp tandemly repeated sequence isolated from nuclear envelopes of chicken erythrocytes is located predominantly on microchromosomes
Csonka et al. Novel generation of human satellite DNA-based artificial chromosomes in mammalian cells
Ley et al. Molecular cloning of African swine fever virus DNA
Schulte et al. Properties of the human nuclear protein p85Mcm: expression, nuclear localization and interaction with other Mcm proteins
Kunze et al. Localization of the active type I DNA topoisomerase gene on human chromosome 20q11. 2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11. 2-13.1
Mazarakis et al. Isolation and characterisation of a testis-expressed developmentally regulated gene from the distal inversion of the mouse t-complex
Kelleher et al. Epstein-Barr–based episomal chromosomes shuttle 100 kb of self-replicating circular human DNA in mouse cells
Fujii et al. Sperizin is a murine RING zinc-finger protein specifically expressed in haploid germ cells
JP2749042B2 (en) Nuclear factors involved in transcriptional regulation
Linder et al. Reactivation of chicken erythrocyte nuclei in heterokaryons results in expression of adult chicken globin genes.
Schumm et al. Mu-specific properties of a phages containing both ends of Mu depend on the relative orientation of Mu end DNA fragments
Toshima et al. Structural organization and chromosomal localization of the mouse tesk1 (testis-specific protein kinase 1) gene
Dieken et al. Homologous modification of human chromosomal genes in chicken B-cell× human microcell hybrids
D'aiuto et al. Physical relationship between satellite I and II DNA in centromeric regions of sheep chromosomes
Nanda et al. The intron-containing ribosomal protein-encoding genes L5, L7a and L37a are unlinked in chicken

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed